3/27/2013 7:58:38 AM
Becton, Dickinson and Co. just netted FDA approval for a manufactured line of generic injectables aimed at reducing the potential for error. Through a wholly owned subsidiary called BD Rx, the new line of generic prefilled syringes will be manufactured at BD (NYSE: BDX)’s Wilson facility. The products, labeled BD Simplist, are designed to decrease the number of steps in the traditional vial and syringe injection sequence, thereby reducing the potential risk of medication error.
comments powered by